Hemophagocytic lymphohistiocytosis (HLH): A heterogeneous spectrum of cytokine-driven immune disorders.

Abstract

Hemophagocytic lymphohistiocytosis (HLH) comprises a group of life-threatening immune disorders classified into primary or secondary HLH. The former is caused by mutations in genes involved in granule-mediated cytotoxicity, the latter occurs in a context of infections, malignancies or autoimmune/autoinflammatory disorders. Both are characterized by systemic inflammation, severe cytokine storms and immune-mediated organ damage. Despite recent advances, the pathogenesis of HLH remains incompletely understood. Animal models resembling different subtypes of HLH are therefore of great value to study this disease and to uncover novel treatment strategies. In this review, all known animal models of HLH will be discussed, highlighting findings on cell types, cytokines and signaling pathways involved in disease pathogenesis and extrapolating therapeutic implications for the human situation.

• Authors: Ellen Brisse, Carine H Wouters, Patrick Matthys
• Journal: Cytokine & growth factor reviews (Cytokine Growth Factor Rev) Vol. 26 Issue 3 Pg. 263-80 (Jun 2015) ISSN: 1879-0305 [Electronic] England
• PMID: 25466631 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: Copyright © 2014 Elsevier Ltd. All rights reserved.

Chemical References

• Cytokines

Topics

• Animals
• Cytokines (immunology)
• Disease Models, Animal
• Humans
• Lymphohistiocytosis, Hemophagocytic (drug therapy, immunology)